chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Site reaction at injection site was red; Site reaction at injection site was swollen; Site reaction at injection site was hot; Bumpy rash on her neck; Skin on her face had a sandpaper feeling, chapped; Lower eye puffy; Lower eye reddish; Red face; Swollen face and cheeks; Hive on face; A spontaneous report was received from a nurse concerning a 48-year-old female patient, who was the patient, who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced eye swelling, eye redness, neck rash, dry skin face, injection site warmth, hive on face, face and cheek swelling, injection site redness, and injection site swelling.  The patient's medical history, as provided by the reported, included hives.  No relevant concomitant medications were reported.  On 29 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Batch/Lot Number: 025J202A/039K20A) in her right deltoid for prophylaxis of COVID-19 infection.   On 29 Dec 2020, the patient had a dime-sized raised hive on her face. Treatment included cetirizine.  On 30 Dec 2020, the patient's lower eye was puffy and red; it looked like she was punched in the face.  She took cetirizine and famotidine.  Her face got redder and more swollen, so she took more famotidine. The patient's eyes, nose, and cheeks were swollen.  On 31 Dec 2020, the patient went to urgent care and was prescribed prednisone.  She also took diphenhydramine.  She developed a bumpy rash on her neck which cleared up. The patient's skin was dry and chapped.  On 06 Jan 2020, the patient's symptoms were back to normal after tapering off the steroids.  The patient was still experiencing a hot, red, and swollen injection site reaction.  She didn't have facial fillers.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the events, eye swelling, eye redness, neck rash, dry skin face, hive on face, face and cheek swelling, was considered recovered/resolved on 06 Jan 2021.  The outcome of the events, injection site redness, injection site warmth, and injection site swelling, was considered not recovered/resolved.; Reporter's Comments: This case concerns a 48-year-old female patient with medical history of hives, who received their first of two planned doses of mRNA-1273 (Lot 025J202A/039K20A), and who experienced the non-serious listed events of injection site redness and injection site swelling, and experienced the non-serious unlisted events of eye swelling, eye redness, neck rash, dry skin, injection site warmth, hive on face, face and cheek swelling, and erythema (face).  Based on the current available information and temporal association between the use of the product and the onset of events starting on the day of vaccination, a causal relationship cannot be excluded and the events are considered possibly related to the vaccine.  The patient's medical history of hives remains a confounder for the events.
Thrombocytopenia, low platelets, petechiae, headache and tiredness.
FACIAL FLUSHING, ITCHING OF HANDS, TIGHTNESS IN THROAT. ITCHING OF FACE AND NECK.
Vomiting 1hr p/being administered Cholera & Typhoid vax concurently, pt devel vomiting, diarrhea, fever, chills, weakness, & blistering of mouth & nasal passages; sx persisted for 24-48 hrs;
Hot flashes; Itchy; Nausea; Fatigue; Headache; Asthma attack (difficulty breathing); Arm soreness; Quarter size bruise at injection site; This is a spontaneous report from a contactable consumer, the patient. A 44-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 02Apr2021 at 09:45 (at the age of 44-year-old) as a single dose for COVID-19 immunisation. Medical history included asthma and nervous system itch. The patient has taken unspecified concomitant medications. The patient had unspecified known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 02Apr2021 at 11:00, the patient experienced hot flashes, itchy, nausea, fatigue, head ache, asthma attack (difficulty breathing), arm soreness and a quarter size bruise at injection site. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events which included treatment with asthma inhaler and TYLENOL from an unknown start date to an unknown stop date. The clinical outcome of the event arm soreness recovered on an unknown date after a duration of 3 days. The clinical outcome of the events hot flashes, itchy, nausea, fatigue, head ache, asthma attack (difficulty breathing) and a quarter size bruise at injection site was recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
as authorized by the health department  we were given the ok to give her the second dose to complete the series.
Pfizer Covid vaccine administered at 1401 on 5/26/2021.   1413 - in observation room, pt noticed a rash (red/blotchy) around injection site. No pain/itching at site. No other symptoms reported.   Pt monitored for 30 minutes by 2 RNs following vaccine administration. By the end of 30 minutes, rash improving without intervention.
This spontaneous report was received from a medical assistant referring to unspecified amount of patients of unknown age and gender. No information was provided regarding the patient's medical history, concurrent conditions or concomitant medications. On unknown dates, the patients were vaccinated with improperly stored GARDASIL 9 lot # N019923 and expiration date on 28-APR-2019 (dose and route of administration were no provided) for prophylaxis. The doses of GARDASIL 9 were exposed to a temperature excursion of 47 degrees Fahrenheit (°F) to 77 °F during a time frame of 2 hours 45 minutes which was detected by the data logger. There was no prior temperature excursion and no adverse events were reported. This is one of the several reports received from the same reporter.; Sender's Comments: US-009507513-1709USA009967: US-009507513-1709USA010122:
Within 10 minutes, post vax 1st Anthrax, pt had a syncopal episode (probable vaso-vagal). 24 hours later, pt complained of numbness and tingling in fingertips, malaise and flushing.  04/03/2001: " I do not want my medical records accessed by the VAERS.  My "reaction" to the shot was diagnosed as an anxiety reaction to receiving a shot in general.  I have had similar reaction to cortisone shot years prior.  I have received two other anthrax shots with no adverse reactions.  I have filled out the Anthrax adverse event follow up form, I apologize for failing to respond sooner.  Patient recovered from adverse event."
arm swelled up in her muscles for 4-5 days; sore; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (arm swelled up in her muscles for 4-5 days) and MYALGIA (sore) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Apr-2021, the patient experienced PERIPHERAL SWELLING (arm swelled up in her muscles for 4-5 days) and MYALGIA (sore). At the time of the report, PERIPHERAL SWELLING (arm swelled up in her muscles for 4-5 days) and MYALGIA (sore) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication was not reported.  The patient was treated with cold pack with no relief.
8 days after receiving the vaccine, woke up with stiff neck, was watching the morning news and couldn't move, within 30 min, was very painful.  Took robaxin rx, and tylenol, which eased the stiff neck and took another dose at bedtime, and was okay after that.  She feels that her neck continues to be tight, but can function normally.  Same thing happened after 1st COVID vaccine, other than it started same day, it was reported to VEARS.
left injection arm soreness; This spontaneous case was reported by a patient and describes the occurrence of VACCINATION SITE PAIN (left injection arm soreness) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 31-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 01-Jan-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced VACCINATION SITE PAIN (left injection arm soreness). At the time of the report, VACCINATION SITE PAIN (left injection arm soreness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   This case was linked to MOD-2021-086280 (Patient Link).
Per patient and mother, Shad felt "funny" later in the day after receiving varivax. Noted dizziness and wheezing when running at football and had to sit out. He had been practicing without these symptoms for 2 weeks prior to this. Resting releived symptoms, symptoms recur with return to activity. Continues to have this pattern 2 wks after event.
Administration was given proximal to intended location of deltoid muscle. Believed to have punctured bursa causing bursitis. Patient reported immediate pain upon injection reporting pain scale 10/10. Patient reported continual pain in upper arm and shoulder near acromion. Patient has been taking acetaminophen 500 mg twice daily to mitigate pain. At time of this report, patient still reports pain 5/10.
The patient started scream not stop x2 hours. Patient was given Tylenol at the time of vaccines and again 6pm when Sx started.
Usual expected side effects ( fever, muscle aches, arm pain, headache for 24 hours) PLUS red upraised rash with uneven border approximately 5? x 3 ? increasing in severity. This is day 5+ and it is continuing to grow and look more red. It feels like bad sunburn with itching. This is not at the  injection site but starts about two inches below.
Patient described rash/cyst-like nodules around injection site of right deltoid muscle. (8-10 in number). Also report headache for 2 days. Nodules seem inflamed or red on 9/14/10.
When he went to smile, smile was off. Left side of his face, eye was not blinking properly. Left forehead and eyebrow, check and lip didn't move. Left eye can't close completely.
Series of myoclonic sz developed 2 wks p/DTP #1 administered on 29OCT90. Terminated following administration of Phenobarbital.
I was working the Back to School Shots event. I was giving pt. 2 shots he needed for school: polio and Td. He was accompanied by his father. allergies, current medications, and education was reviewed with the parent.  I then walked over to, who was the nurse drawing up medication for this event. I told her I needed 2 vaccines, the polio and Td. I brought both vaccines back to the table, but did not double check the vaccines I was given. I gave the polio vaccine first, and then gave him the TdaP vaccine. After reviewing paperwork, and charting the vaccine I gave, I realized the I gave the patient the wrong vaccine, he was given a vaccine that should be only given to children 7 years and older. After this medication was made, I alerted the parent and team lead. We then then told the parent we wanted to monitor the child for 30 minutes, to make sure he did not have any reaction.  Patient was monitored, and had no reaction, alerted to patient to monitor the patient, and someone from the Health Dept would reach out to the patient this week.
After waiting my 15 minutes I got up to leave. I put my children in the vehicle and then called my husband. I noticed the tip and the right side of my tongue was tingly. I felt as if I had a lump in my throat. I looked in the mirror and my tongue was not red or swollen. I stayed in the parking lot and spoke with my husband incase I did have an anaphylactic reaction. My symptoms started getting better and fading around 9:45 AM, so I left the parking lot. I notified the vaccine clinic via text message of the reaction after I had already left the site. They offered me to see a provider, but the symptoms already started to go away, so he advised me to take benadryl when I got to my location.  Once I got to my location benadryl was no longer needed because the symptoms were gone. This was about 45 minutes to an hour after the vaccine was administered.
TOOK UNREFRIGERATED DOSES; This spontaneous case (PVX2019-1064) was received from consumer on 01-May-2019. It describes a 37-year-old female consumer who "took unrefrigerated doses", while being on oral Vivotif (one dose every other day) for typhoid fever prophylaxis.  Case report: The consumer took unrefrigerated doses of Vivotif. The first and last dose were taken on 01-Apr-2019 and 07-Apr-2019, respectively.  Action taken with Vivotif was not applicable.  The clinical outcome of the event "took unrefrigerated doses" was unknown.  Company's Comment: The causality of the event "took unrefrigerated doses" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event "took unrefrigerated doses" was considered as not applicable.
Hives in mouth and over body, swollen throat, itchy skin and eyes lasting about 1 hour resolving on own.
too weak; This is a spontaneous report from a Contactable consumer. This consumer reported for a 79 year old male patient (Father) that he received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number, Expiry Date: Unknown), via an unspecified route of administration on an unspecified date as dose 2, single for covid-19 immunization. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot Number, Expiry Date: Unknown), via an unspecified route of administration on an unspecified date as dose 1, single for covid-19 immunization. Medical history included arrhythmia, heart failure, CKD, T2DM, high cholesterol. He had the Covid infection in Nov2020 which put him in the hospital for a week and wiped him out (bed-ridden) for at least a month after he returned from the hospital in Nov2020. Patient had his 2nd Covid vaccine on Friday (unspecified date) and on Saturday (unspecified date) he was on the bedroom floor, he was too weak to get back into bed after crawling to the bathroom. Reporter's sister would give the reporter an update later that day on his status. Reporter notified that he felt much better just after reporter's initial report, on 22Feb (Monday). The outcome for the all the event was recovering. No follow-up attempts are possible, information about lot (or) batch no. cannot be obtained
SCRATCHY PATCHES AND BLISTERS ON MY INNER ARM NEXT TO THE INJECTION SITE.
No additional adverse event; Nurse calling to inquire about GARDASIL 9 dosing and reported a patient recieved her third dose of GARDASIL 9 too early/Patient first dose 19-JUL-2018, second dose was 19-NOV-2020, and the third dose was 22-JAN-2021; This spontaneous report was received from a nurse regarding a female patient of unknown age. The patient's concurrent conditions, pertinent medical history, drug reactions, allergies, and concomitant therapies were not provided.   On 19-JUL-2018, the patient was vaccinated with the first dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9), on 19-NOV-2020 received the second dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9), and on 22-JAN-2021 received the third dose of HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) 0.5 milliliter, intramuscularly (lot number, and expiration date were not provided) for prophylaxis. On 22-JAN-2021, the nurse called to inquire about HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast) (GARDASIL 9) dosing and reported that the patient received the third dose too early (inappropriate schedule of product administration).No additional adverse events.
Upper right thigh with area of erythematous, raised skin warm to touch - 11 1/2 X 6cm. Patient c/o pruritus over area.
faint red rash from waist down through legs within in 1 hour of receiving vaccine. Took Zyrtec, which did not help. 4 hours later, rash all over body - took benadryl which did help. Then proceeded to be up all night vomiting and 103F temp and body aches and severe headache. Next day - 24 hours after vaccine - temp 102, severe body aches and headache. Took tylenol, but fever and bodyaches did not respond to tylenol.
This spontaneous report as received from a medical assistant refers to a 12 month old infant patient of unknown gender. The patient's concurrent conditions, medical history, concomitant medications, drug reactions and allergies were not reported. On 16-OCT-2018, the patient was vaccinated with improperly stored dose of VAQTA ped 0.5 ml vial (dose, frequency and route were not reported) (lot # R009953, expiry date: 12-JUN-2019) for prophylaxis. On 06-SEP-2018, the vaccine was exposed to the temperature of 32.21 degree Fahrenheit (°F) (32F to 35 F) for 3.5 hours. Previous excursion was 50.37 °F for 4.5 hours as recorded by a data logger. No adverse effect was reported. No product quality complaint was involved. This is one of the several reports received from the same reporter source. Sender's Comments: US-009507513-1809USA002868:Original Case : 1809USA002868; US-009507513-1902USA009324:Original Case : 1902USA009323; US-009507513-1902USA009325:Original Case : 1902USA009323; US-009507513-1902USA009326:Original Case : 1902USA009323.
Headache; Nausea; Fatigue; I don't have any appetite; Indigestion; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 57 year-old female patient received bnt162b2 (BNT162B2) (Lot number: EW0172) at the age of 57 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEADACHE (non-serious), outcome "unknown", described as "Headache"; NAUSEA (non-serious), outcome "unknown", described as "Nausea"; FATIGUE (non-serious), outcome "unknown", described as "Fatigue"; DECREASED APPETITE (non-serious), outcome "unknown", described as "I don't have any appetite"; DYSPEPSIA (non-serious), outcome "unknown", described as "Indigestion". Therapeutic measures were taken as a result of headache, nausea, fatigue, decreased appetite, dyspepsia.  Additional information: Treatment: Nurse stated, "Ibuprofen. When I had indigestion so I took Protonix. I had Indigestion also last night. Today, I have the nausea and the headache. The headache is the worst.   No follow-up attempts are possible. No further information is expected.
Rash distal. Vértigo Dolor muscular y articular generalizado Fiebre Gripe Escurrimiento nasal Cefalea Dolor abdominal Diarrea Náuseas Disgeusia Fatiga
No immediate ill effects after this second shot of the Moderna vaccine at 10 am. Worked that day and went home, woke up around 2 am with sweats and nausea and headache which became progressively worse through the day prohibiting any activity. Dry heaves and severe headache with dizziness lasted until 4 pm or so. I did take Ondansetron at 12 noon to limit nausea. Worked the following day with few physical symptoms but very irritable. The next day (Saturday) woke with headache and slight nausea which became worse as the day wore on, limiting activity but I was able to get chores done, though I was very lethargic. The next day was much better. Worked on Monday the 12th of April and felt well. Fell ill again with similar but less severe symptoms, though marked nausea and dry heaving again. Slept until approximately 2pm and started writing this report. 4/13/2021
For above - unsure of which MenB was given - this office was not the office that gave injection.  Adverse reaction: pt developed a rash at the site of injection ~4 days after vaccination. On a side note, pt had previously been vaccinated with meninA (combined vaccine) when she was 16 and again about a month prior to receiving the MenB (so got an extra shot of MenA).
Patient was 17 years old at time of vaccination and manufacturer recommends 18 and older to receive shot.
< 24 hours s/p vaccine, pt had hypersalivation, abd distention, irritability, diff with breathing secondary to increased saliva. Resolved with BM 28 hours later.
administration of expired Moderna vaccine; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (administration of expired Moderna vaccine) in a 47-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 02-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (administration of expired Moderna vaccine). On 02-Dec-2021, EXPIRED PRODUCT ADMINISTERED (administration of expired Moderna vaccine) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medication of the patient was not reported.   No treatment was given to the patient.   The vaccines were stored in freezer, were taken out one to two vials and placed in fridge each day as needed.
Bright red, swelling, hot to touch; migrated down arm. Worsened over the next 48 hrs. Called my Dr. They said it was a "dermal shot" not injected in muscle. Symptoms worsened. Went to ER.-Dr. said it was a moderate allergic reaction. Prescribed Prednisone. It took approx 10 days to go down. 3 weeks later-still have a discolored "bruise" & can see the injection spot. Follow-up with Allergist; she said it was likely the preservatives and the fact it was not injected in the muscle. She said I must get a traditional flu shot injected in the muscle next yr and preservative-free. I had never had a flu shot reaction before.
came down with Covid this past January 20; This spontaneous case was reported by a patient family member or friend and describes the occurrence of COVID-19 (came down with Covid this past January 20) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.   In 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Feb-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 20-Jan-2023, the patient experienced COVID-19 (came down with Covid this past January 20). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) at an unspecified dose and frequency. On 25-Jan-2023, COVID-19 (came down with Covid this past January 20) had resolved.            No concomitant medication was provided by reporter.  Patient received Dose 2 Moderna Covid vaccine in 2022. Patient received First booster dose of Moderna on 05-Feb-2022. Patient did not get the second booster and came down with Covid this past 20 Jan and recovered on 25 Jan with the help of Plaxovid.